Sanofi
ProfileJobs (1.71 k)

Sanofi

Suggest Edit
    • HealthcareManufacturing & Industrialbiotechdrug developmentmedical devicespharmatherapy

    Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

    Revenue(FY, 2015)
    €37.1 B
    TypePublic
    HQParis, FR
    Founded2004
    Size (employees)106,859 (est)
    Websiteen.sanofi.com
    Sanofi was founded in 2004 and is headquartered in Paris, FR
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Key People/Management at Sanofi

    Olivier Brandicourt

    Olivier Brandicourt

    CEO
    Olivier Charmeil

    Olivier Charmeil

    Executive Vice President and General Manager
    Jerome Contamine

    Jerome Contamine

    Executive Vice President & Chief Financial Officer
    Karen Linehan

    Karen Linehan

    Executive Vice President, Legal Affairs and General Counsel
    David Loew

    David Loew

    Executive Vice President and General Manager of Sanofi Pasteur
    Philippe Luscan

    Philippe Luscan

    Executive Vice President, Global Industrial Affairs
    Show more

    Sanofi Office Locations

    Sanofi has offices in Singapore, Paris, Bridgewater, Macquarie Park and in 9 other locations
    Paris, FR (HQ)
    54, rue La Boétie
    Macquarie Park, AU
    Building D, 12-24 Talavera Road
    Ontario, CA
    1755 Steeles avenue West
    Beijing, CN
    7th floor, n°112, Jian Guo Lu, Chaoyang District
    Hong Kong, HK
    Room 2504-2511, Windsor House, 311, Gloucester Road, Causeway Bay
    New Delhi, IN
    D-2, Fourth Floor, Southern Park, DDA Commercial Centre, Saket
    Show all (13)
    Report incorrect company information

    Sanofi Financials and Metrics

    Sanofi Revenue

    Embed Graph
    Sanofi's revenue was reported to be €37.06 b in FY, 2015 which is a 9.7% increase from the previous period.
    EUR

    Revenue (FY, 2015)

    		37.1b

    Revenue growth (FY, 2014 - FY, 2015), %

    		9.7%

    Gross profit (FY, 2015)

    		26.1b

    Gross profit margin (FY, 2015), %

    		70.5%

    Net income (FY, 2015)

    		4.4b
    EURFY, 2013FY, 2014FY, 2015

    Revenue

    		33.0b33.8b37.1b

    Revenue growth, %

    		2%10%

    Cost of goods sold

    		10.3b10.2b10.9b

    Gross profit

    		22.6b23.5b26.1b
    show all
    EURFY, 2013FY, 2014FY, 2015

    Cash From Operating Activities

    		6.4b6.3b7.2b
    show all
    EURY, 2015

    Revenue/Employee

    		365.4k
    Show all financial metrics

    Sanofi Operating Metrics

    Y, 2013Y, 2014Y, 2015Y, 2016

    Drugs Approved by FDA

    		1

    Phase III Trials Products

    		11 9 8 7

    Projects in R&D Pipeline

    		36 32 34 43
    Show all operating metrics

    Sanofi Acquisitions / Subsidiaries

    Acquired CompanyDateDeal Size
    Ablynx January 29, 2018$4.80 b
    Bioverativ January 22, 2018$11.60 b

    Sanofi Revenue Breakdown

    Embed Graph

    Sanofi revenue breakdown by business segment: 80.4% from Pharmaceuticals, 12.8% from Vaccines and 6.8% from Animal Health

    Report incorrect company information

    Competitors

    Celgene
    Healthcare - Public
    Regeneron Pharmaceuticals
    Healthcare - Public
    AdoRx Therapeutics
    Healthcare - Private
    Escient Pharmaceuticals
    Healthcare - Private
    Compare competitors

    Sanofi Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Sanofi Company Life and Culture

    Report incorrect company information
    Download PDF